AYTU BioPharma, Inc. Common Stock (AYTU) Stock Price

AYTUStock

$2.04−12.07%52W

Market Cap$22.17M

P/E—

PEG Ratio—

Div yield—

Beta0.18

AYTU Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-30.22%

Price vs S&P 500 (4W)-2.67%

VGM Score62.90

P/CF (Annual)6.76x

Book Value / Share (Quarterly)$3.29

P/TBV (Annual)2.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-18.77%

Cash Flow / Share (Quarterly)$0.30

Price vs S&P 500 (YTD)-33.47%

Gross Margin (TTM)63.95%

Net Profit Margin (TTM)-24.76%

EPS (TTM)$-1.49

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-1.49

Revenue Growth (5Y)-2.58%

EPS (Annual)$-1.16

ROI (Annual)-27.25%

Gross Margin (Annual)63.95%

Net Profit Margin (5Y Avg)-38.64%

Cash / Share (Quarterly)$2.45

Revenue Growth QoQ (YoY)6.42%

ROA (Last FY)-13.57%

Revenue Growth TTM (YoY)-13.27%

EBITD / Share (TTM)$-0.45

ROE (5Y Avg)-89.70%

Operating Margin (TTM)-14.44%

Cash Flow / Share (Annual)$0.30

P/B Ratio0.63x

P/B Ratio (Quarterly)0.65x

Net Income / Employee (Annual)$-173,800

EV / Revenue (TTM)0.22x

Net Interest Coverage (TTM)-1.41x

ROA (TTM)-12.29%

EV / EBITDA (TTM)3.50x

EPS Incl Extra (Annual)$-1.16

Current Ratio (Annual)1.13x

Quick Ratio (Quarterly)0.90x

3-Month Avg Trading Volume0.03M

52-Week Price Return-12.07%

EV / Free Cash Flow (Annual)3.96x

Revenue / Employee (TTM)$702,100

Tangible BV / Share (Quarterly)$16.13

P/S Ratio (Annual)0.39x

Asset Turnover (Annual)0.55x

52-Week High$3.06

Operating Margin (5Y Avg)-31.66%

EPS Excl Extra (Annual)$-1.16

CapEx CAGR (5Y)-58.44%

26-Week Price Return-20.31%

Quick Ratio (Annual)0.90x

13-Week Price Return-5.12%

Total Debt / Equity (Annual)0.48x

Current Ratio (Quarterly)1.13x

Enterprise Value$12.89M

Revenue / Share Growth (5Y)-43.62%

Asset Turnover (TTM)0.50x

Book Value / Share Growth (5Y)-49.31%

Revenue / Employee (Annual)$702,100

Inventory Turnover (Annual)2.27x

Pretax Margin (Annual)-24.72%

Cash / Share (Annual)$2.45

3-Month Return Std Dev37.13%

Gross Margin (5Y Avg)61.93%

Net Income / Employee (TTM)$-173,800

ROE (Last FY)-40.40%

Net Interest Coverage (Annual)-0.62x

EPS Basic Excl Extra (Annual)$-1.16

P/FCF (TTM)2.75x

Receivables Turnover (TTM)2.13x

EV / Free Cash Flow (TTM)3.96x

Total Debt / Equity (Quarterly)0.48x

EPS Incl Extra (TTM)$-1.49

Receivables Turnover (Annual)2.13x

ROI (TTM)-29.27%

P/S Ratio (TTM)0.39x

Pretax Margin (5Y Avg)-37.36%

Revenue / Share (Annual)$4.67

Tangible BV / Share (Annual)$37.21

Forward P/E8.83x

Price vs S&P 500 (52W)-27.60%

Year-to-Date Return-21.54%

5-Day Price Return3.55%

EPS Normalized (Annual)$-1.16

ROA (5Y Avg)-25.90%

Net Profit Margin (Annual)-24.76%

Month-to-Date Return-4.67%

Cash Flow / Share (TTM)$-3.85

EBITD / Share (Annual)$-0.47

Operating Margin (Annual)-14.44%

LT Debt / Equity (Annual)0.26x

P/CF (TTM)6.76x

ROI (5Y Avg)-59.47%

LT Debt / Equity (Quarterly)0.26x

EPS Basic Excl Extra (TTM)$-1.49

P/TBV (Quarterly)1.67x

P/B Ratio (Annual)0.65x

Inventory Turnover (TTM)2.27x

Pretax Margin (TTM)-24.72%

Book Value / Share (Annual)$3.29

Price vs S&P 500 (13W)-7.80%

Beta0.18x

P/FCF (Annual)6.82x

Revenue / Share (TTM)$4.67

ROE (TTM)-52.89%

52-Week Low$1.80

vGradeA

gGradeD

mGradeB

vgmGradeB

AYTU Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Sep 22, 2026	-$0.35	-$0.06	+82.69%(+$0.29)
Q1 2026	May 13, 2026	-$0.42	-$0.41	+2.38%(+$0.01)
Q4 2025	Feb 3, 2026	-$0.49	-$0.23	+52.89%(+$0.26)
Q3 2025	Nov 13, 2025	-$0.20	-$0.09	+52.10%(+$0.10)
Q2 2025	Sep 23, 2025	-$0.06	-$0.08	-27.33%(-$0.02)

AYTU Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.11

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AYTUAYTU BioPharma, Inc. Common Stock	A	D	B	0.4x	-13.3%	64.0%	—	$2.04
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About AYTU BioPharma, Inc. Common Stock

Aytu BioPharma is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products, focusing on pediatric conditions including ADHD. The company is building a clinical pipeline that includes a prospective treatment for vascular Ehlers-Danlos Syndrome, a rare genetic disorder associated with significant morbidity.